Episode

Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

Podcast: The Uromigos
Published: May 29, 2026
Duration seconds: 2432
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-504-ASCO-2026---ADC-Drug-Development-in-Urothelial-Cancer-e3jsa4o
Audio: https://anchor.fm/s/13347ea8/podcast/play/120514136/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-25%2F424851413-44100-2-cf14be68f94d8.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer
Markdown: /podcast/the-uromigos-1214845/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.